Initial Statement of Beneficial Ownership (3)

Date : 05/15/2019 @ 9:12PM
Source : Edgar (US Regulatory)
Stock : Marker Therapeutics Inc (MRKR)
Quote : 4.31  -0.2 (-4.43%) @ 11:01PM

Initial Statement of Beneficial Ownership (3)

FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Koneru Mythili

2. Date of Event Requiring Statement (MM/DD/YYYY)
5/9/2019 

3. Issuer Name and Ticker or Trading Symbol

Marker Therapeutics, Inc. [MRKR]

(Last)        (First)        (Middle)

3200 SOUTHWEST FREEWAY, SUITE 2240

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
Snr VP, Clinical Development /

(Street)

HOUSTON, TX 77027       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy)   (1)   (1) 2/7/2029   Common Stock   10000   $5.10   D    
Employee Stock Option (Right to Buy)   (2)   (2) 2/7/2029   Common Stock   300000   $5.10   D    

Explanation of Responses:
(1)  Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended for service as the Company's Senior Vice President, Clinical Development which vested immediately. The option exercise price is the closing price on the date of the grant, February 7, 2019.
(2)  Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended for service as the Company's Senior Vice President, Clinical Development. One quarter of the shares vest on the first anniversary of the grant date, the remainder of the shares vest in monthly installments over a three year period upon the continued employment of the Reporting Person by the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, February 7, 2019.

Remarks:
* Mr. Mark A. Catchur is signing as Attorney-in-Fact pursuant to power of attorney dated May 9, 2019 granted by the Reporting Person, a copy of which is filed as an exhibit and incorporated herein by reference.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Koneru Mythili
3200 SOUTHWEST FREEWAY
SUITE 2240
HOUSTON, TX 77027


Snr VP, Clinical Development

Signatures
/s/ Mark A. Catchur as Attorney-In-Fact for Mythili Koneru* 5/15/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart

1 Year : From Oct 2018 to Oct 2019

Click Here for more Marker Therapeutics Charts.

Marker Therapeutics (NASDAQ:MRKR)
Intraday Stock Chart

Today : Wednesday 16 October 2019

Click Here for more Marker Therapeutics Charts.

Latest MRKR Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.